Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Meta-analysis
100%
Major Adverse Cardiovascular Events
100%
Randomized Controlled Trial
100%
Biologic Therapy
100%
Cardiovascular Events
100%
Chronic Plaque Psoriasis
100%
Placebo
57%
Anti-interleukin-23
57%
Interleukin-12 (IL-12)
42%
Mantel-Haenszel
42%
Anti-tumor Necrosis Factor Agents
42%
Placebo-controlled
28%
Interleukin-23 (IL-23)
28%
Risk Difference
28%
Briakinumab
28%
95% Confidence Interval
28%
Control Phase
28%
Ustekinumab
28%
Randomized Placebo-controlled Trial
14%
Myocardial Infarction
14%
Cardiovascular Mortality
14%
Monotherapy
14%
Monoclonal Antibody
14%
Adalimumab
14%
Cerebrovascular Accident
14%
Treatment Phase
14%
Safety Outcomes
14%
Etanercept
14%
Data Extraction
14%
Fixed Effects Model
14%
Infliximab
14%
Poster Presentation
14%
No Significant Difference
14%
Anti-tumor Necrosis Factor Therapy
14%
Absolute Risk Difference
14%
Psoriasis Disease
14%
Tumor Necrosis Factor-α
14%
Primary Outcome Measure
14%
Composite Endpoint
14%
Exclusion Criteria
14%
Cochrane Central Register of Controlled Trials
14%
Psoriatic Arthritis
14%
Effect Measure
14%
P40 Subunit
14%
Accident Death
14%
Zero Events
14%
I2 Statistic
14%
Statistical Heterogeneity
14%
Ovid MEDLINE
14%
Trial Results
14%
Anti-interleukin
14%
Pharmacology, Toxicology and Pharmaceutical Science
Randomized Controlled Trial
100%
Placebo
100%
Interleukin 12
100%
Psoriasis Vulgaris
100%
Cardiovascular Disease
100%
Tumor Necrosis Factor Inhibitor
42%
Tumor Necrosis Factor
28%
Ustekinumab
28%
Briakinumab
28%
Heart Infarction
14%
Cerebrovascular Accident
14%
Interleukin 23
14%
Interleukin 23 Antibody
14%
Monoclonal Antibody
14%
Psoriasis
14%
Monotherapy
14%
Infliximab
14%
Etanercept
14%
Adalimumab
14%
Psoriatic Arthritis
14%